Capturing a Comprehensive Picture of Biological Events From Adverse Outcome Pathways in the Drug Exposome

被引:1
|
作者
Wu, Qier [1 ]
Bagdad, Youcef [1 ]
Taboureau, Olivier [2 ]
Audouze, Karine [1 ]
机构
[1] Univ Paris, INSERM U1124, CNRS ERL 3649, Paris, France
[2] Univ Paris, INSERM U 1133, CNRS UMR 8251, Paris, France
关键词
network science; AOP; bipartite network; drug-AOP; AON; NAM; SYSTEMS BIOLOGY; EXPOSURE; ENVIRONMENT; TOXICOLOGY; RESOURCE; NETWORK; MODELS; GENOME;
D O I
10.3389/fpubh.2021.763962
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: The chemical part of the exposome, including drugs, may explain the increase of health effects with outcomes such as infertility, allergies, metabolic disorders, which cannot be only explained by the genetic changes. To better understand how drug exposure can impact human health, the concepts of adverse outcome pathways (AOPs) and AOP networks (AONs), which are representations of causally linked events at different biological levels leading to adverse health, could be used for drug safety assessment.Methods: To explore the action of drugs across multiple scales of the biological organization, we investigated the use of a network-based approach in the known AOP space. Considering the drugs and their associations to biological events, such as molecular initiating event and key event, a bipartite network was developed. This bipartite network was projected into a monopartite network capturing the event-event linkages. Nevertheless, such transformation of a bipartite network to a monopartite network had a huge risk of information loss. A way to solve this problem is to quantify the network reduction. We calculated two scoring systems, one measuring the uncertainty and a second one describing the loss of coverage on the developed event-event network to better investigate events from AOPs linked to drugs.Results: This AON analysis allowed us to identify biological events that are highly connected to drugs, such as events involving nuclear receptors (ER, AR, and PXR/SXR). Furthermore, we observed that the number of events involved in a linkage pattern with drugs is a key factor that influences information loss during monopartite network projection. Such scores have the potential to quantify the uncertainty of an event involved in an AON, and could be valuable for the weight of evidence assessment of AOPs. A case study related to infertility, more specifically to "decrease, male agenital distance" is presented.Conclusion: This study highlights that computational approaches based on network science may help to understand the complexity of drug health effects, with the aim to support drug safety assessment.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Detecting potential signals of adverse drug events from prescription data
    Zhan, Chen
    Roughead, Elizabeth
    Liu, Lin
    Pratt, Nicole
    Li, Jiuyong
    [J]. ARTIFICIAL INTELLIGENCE IN MEDICINE, 2020, 104
  • [32] An ensemble method for extracting adverse drug events from social media
    Liu, Jing
    Zhao, Songzheng
    Zhang, Xiaodi
    [J]. ARTIFICIAL INTELLIGENCE IN MEDICINE, 2016, 70 : 62 - 76
  • [33] Pharmaocepidemology (PE) and adverse drug events (ADE): From identification to prevention
    Gilbert, A.
    Roughead, E.
    Peck, R.
    Killer, G.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S75 - S75
  • [34] A method for systematic discovery of adverse drug events from clinical notes
    Wang, Guan
    Jung, Kenneth
    Winnenburg, Rainer
    Shah, Nigam H.
    [J]. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2015, 22 (06) : 1196 - 1204
  • [35] Adverse drug events resulting from patient errors in older adults
    Field, Terry S.
    Mazor, Kathleen M.
    Briesacher, Becky
    DeBellis, Kristin R.
    Gurwitz, Jerry H.
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2007, 55 (02) : 271 - 276
  • [36] Validation of a prediction rule for adverse cardiovascular events from drug overdose
    Manini, Alex F.
    Richardson, Lynne D.
    Vlahov, David
    Hoffman, Robert S.
    [J]. CLINICAL TOXICOLOGY, 2016, 54 (04) : 432 - 432
  • [37] Adverse Outcome Pathways: Moving from a Scientific Concept to an Internationally Accepted Framework
    Hecker, Markus
    LaLone, Carlie A.
    [J]. ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY, 2019, 38 (06) : 1152 - 1163
  • [38] Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways
    Lopez-Pascual, Ernesto
    Rienda, Ivan
    Perez-Rojas, Judith
    Rapisarda, Anna
    Garcia-Llorens, Guillem
    Jover, Ramiro
    Castell, Jose V.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (10)
  • [39] From Causal Networks to Adverse Outcome Pathways: A Developmental Neurotoxicity Case Study
    Ramsak, Ziva
    Modic, Vid
    Li, Roman A. A.
    vom Berg, Colette
    Zupanic, Anze
    [J]. FRONTIERS IN TOXICOLOGY, 2022, 4
  • [40] Biological treatment in rheumatic diseases:: results from a longitudinal surveillance:: adverse events
    Konttinen, L.
    Honkanen, V.
    Uotila, T.
    Pollanen, J.
    Waahtera, M.
    Romu, M.
    Puolakka, K.
    Vasala, M.
    Karjalainen, A.
    Luukkainen, R.
    Nordstrom, D. C.
    [J]. RHEUMATOLOGY INTERNATIONAL, 2006, 26 (10) : 916 - 922